BIONIZ

Description

With over 50 years of combined experience in the field of immunology, Bioniz scientists have developed a novel platform technology to develop first-in-class therapeutics that inhibits the activated immune response narrowly without compromising the entire immune system. This technology is based on rationale-drug design and engineering of non-antibody molecules against well-characterized cellular targets, a strategy that is referred to as targeted therapy.

Companies nearby